{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:02:38Z","timestamp":1781614958155,"version":"3.54.5"},"reference-count":34,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":58,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"\n Objective<\/jats:title>\n To assess the long-term effect of bimekizumab, a dual inhibitor of IL-17A and IL-17F, on patient-reported symptoms, function and health-related quality of life (HRQoL) in patients with axial spondyloarthritis (axSpA) from phase 3 studies and their open-label extension.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n BE MOBILE 1 (non-radiographic-axSpA) and 2 (radiographic-axSpA) comprised 16-week double-blind placebo-controlled and 36-week maintenance periods. From week 16, all patients received subcutaneous bimekizumab 160\u2009mg every 4 weeks. At week 52, eligible patients could enrol in the open-label extension BE MOVING and continue bimekizumab treatment. Spinal pain (rated on a numerical rating scale from 0 (no pain) to 10 (maximum pain)), morning stiffness (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) average of Q5\/6), fatigue (BASDAI Q1; Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue subscale), sleep quality (Medical Outcomes Study (MOS) Sleep Scale Index II), physical function (Bath Ankylosing Spondylitis Functional Index (BASFI)) and HRQoL (36-Item Short Form Survey (SF-36) physical component summary (PCS)\/mental component summary (MCS); Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire) were reported to week 104.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 494\/586 (84.3%) patients entered BE MOVING at week 52; 456 completed week 104. Patients reported substantial changes from baseline to week 104 in total spinal pain (\u22124.3), nocturnal spinal pain (\u22124.3), morning stiffness (\u22124.3) and fatigue (BASDAI Q1: \u22123.4; FACIT-Fatigue: +9.9). Over half reported total and nocturnal spinal pain scores \u22643 at week 104. Similar improvements to week 104 were shown in sleep (MOS-Sleep Scale: +10.2), physical function (BASFI: \u22122.9) and HRQoL (SF-36 PCS: +12.4; ASQoL: \u22125.6).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms and their impacts across the full disease spectrum of axSpA over 2 years, underscoring its long-term potential for improving patients\u2019 daily lives.<\/jats:p>\n <\/jats:sec>\n \n Trial registration numbers<\/jats:title>\n \n NCT03928704<\/jats:ext-link>\n ,\n NCT03928743<\/jats:ext-link>\n ,\n NCT04436640<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006013","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:50:28Z","timestamp":1764334228000},"page":"e006013","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-3407","authenticated-orcid":false,"given":"Helena","family":"Marzo-Ortega","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Compan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center, Providence St. Joseph Health and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, University Hospitals, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Bielefeld University, Medical School and University Medical Center, Klinikum Bielefeld, Bielefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Antonietta","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Universit\u00e0 Cattolica del Sacro Cuore, Roma, Italy"},{"name":"Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-9176","authenticated-orcid":false,"given":"Karl","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospital NHS Trust, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8970-4260","authenticated-orcid":false,"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"de la Loge","sequence":"additional","affiliation":[{"name":"UCB, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[{"name":"UCB, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB, Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Vaux","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2025112804501050000_11.4.e006013.1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Comp\u00e1n","year":"2025","journal-title":"Lancet"},{"key":"2025112804501050000_11.4.e006013.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225185"},{"key":"2025112804501050000_11.4.e006013.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1191782","article-title":"The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases","volume":"14","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Front Immunol"},{"key":"2025112804501050000_11.4.e006013.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2025112804501050000_11.4.e006013.5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/acr2.11543","article-title":"The international map of axial spondyloarthritis survey: a US patient perspective on diagnosis and burden of disease","volume":"5","author":"Magrey","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2025112804501050000_11.4.e006013.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2025112804501050000_11.4.e006013.7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"2025112804501050000_11.4.e006013.8","unstructured":"European Medicines Agency (EMA) . Bimekizumab summary of product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf"},{"key":"2025112804501050000_11.4.e006013.9","unstructured":"United States Food and Drug Administration (FDA) . Highlights of prescribing infomation: bimzelx. 2024. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761151s009lbl.pdf"},{"key":"2025112804501050000_11.4.e006013.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216980"},{"key":"2025112804501050000_11.4.e006013.11","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.42282","article-title":"Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its open-label extension study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025112804501050000_11.4.e006013.12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005081","article-title":"Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension","volume":"11","author":"Deodhar","year":"2025","journal-title":"RMD Open"},{"key":"2025112804501050000_11.4.e006013.13","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/rheumatology\/keaf009","article-title":"Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies","volume":"64","author":"Baraliakos","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025112804501050000_11.4.e006013.14","first-page":"23","article-title":"Improved pain, morning stiffness, and fatigue with bimekizumab in axial spondyloarthritis: results from the phase III BE MOBILE studies","volume":"52","author":"Navarro-Comp\u00e1n","year":"2024","journal-title":"J Rheumatol"},{"key":"2025112804501050000_11.4.e006013.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210206"},{"key":"2025112804501050000_11.4.e006013.16","doi-asserted-by":"crossref","first-page":"152571","DOI":"10.1016\/j.semarthrit.2024.152571","article-title":"Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial","volume":"69","author":"Ramiro","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025112804501050000_11.4.e006013.17","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001544"},{"key":"2025112804501050000_11.4.e006013.18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004202","article-title":"Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies","volume":"10","author":"Dubreuil","year":"2024","journal-title":"RMD Open"},{"key":"2025112804501050000_11.4.e006013.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225240"},{"key":"2025112804501050000_11.4.e006013.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"2025112804501050000_11.4.e006013.21","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025112804501050000_11.4.e006013.22","unstructured":"de la Loge C , Voiniciuc D , Taieb V , et al . Psychometric properties and thresholds to guide interpretations of Bath Ankylosing Spondylitis Disease Activity Index Fatigue Question 1 (BASDAI-Q1) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) subscale in axial spondyloarthritis (axSpA). Ghent, Belgium ICS Ghent; 2024."},{"key":"2025112804501050000_11.4.e006013.23","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-024-00769-x"},{"key":"2025112804501050000_11.4.e006013.24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s41687-021-00311-3","article-title":"The development and validation of a revised version of the Medical Outcomes Study Sleep Scale (MOS Sleep-R)","volume":"5","author":"Yarlas","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2025112804501050000_11.4.e006013.25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40744-019-00176-5","article-title":"Assessing physical activity and sleep in axial spondyloarthritis: measuring the gap","volume":"6","author":"Deodhar","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025112804501050000_11.4.e006013.26","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2025112804501050000_11.4.e006013.27","unstructured":"Maruish ME . User\u2019s Manual for the SF-36v2 Health Survey 3rd Edn. Lincoln, RI: QualityMetric Incorporated, 2011."},{"key":"2025112804501050000_11.4.e006013.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"2025112804501050000_11.4.e006013.29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s11136-020-02686-0","article-title":"Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis","volume":"30","author":"Hoepken","year":"2021","journal-title":"Qual Life Res"},{"key":"2025112804501050000_11.4.e006013.30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2024-eular.2292","article-title":"POS0806 Long-term sustained efficacy and safety of bimekizumab across the full spectrum of axial spondyloarthritis: two-year results from two phase 3 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025112804501050000_11.4.e006013.31","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000589"},{"key":"2025112804501050000_11.4.e006013.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.07.021"},{"key":"2025112804501050000_11.4.e006013.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"key":"2025112804501050000_11.4.e006013.34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40744-021-00306-y","article-title":"Cross-walk of the Assessment of Spondyloarthritis International Society Health Index and Ankylosing Spondylitis Quality of Life scores in ankylosing spondylitis and non-radiographic axial spondyloarthritis patients","volume":"8","author":"Pike","year":"2021","journal-title":"Rheumatol Ther"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:50:39Z","timestamp":1764334239000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,28]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-006013"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006013","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}